Cancer Research UK Cambridge Institute

If you are also interested in a career with us, the latest roles are featured on our vacancies page: www.cruk.cam.ac.uk/vacancies/

Atif became interested in a studying computing thanks to a cousin with similar interests. Now he works as a Research Associate in our Ali Group, building AI methods to scale up the data acquisition and analysis of cancer in a spatial context.

Find out more in the latest Behind the Lab Coat.

Sustainability - Cancer Research UK Cambridge Institute The Cancer Research UK Cambridge Institute is driving research forward in as sustainable and environmentally responsible a way as possible.

Find out more about some of the sustainable initiatives driving change at our Institute:

www.cruk.cam.ac.uk/our-strategy...

CRUK CI has achieved Silver Laboratory Efficiency Assessment Framework (LEAF) accreditation! 🧪

The LEAF programme supports labs to reduce their carbon emissions. This award recognises the steps we've taken to implement more sustainable practices across the CI.

@cam.ac.uk @cambridgezero.bsky.social

The cancer treatment pipeline: Inside Cambridge’s bench-to-bedside journey Join us for a free talk and learn about recent discoveries from our Cambridge lab. This talk is part of the Cambridge Festival for 2026.

Tickets and event info: www.eventbrite.co.uk/e/the-cancer...

Thinking about coming to our #CamFest event on the cancer treatment pipeline? Check out this preview with one of our speakers, Professor Jason Carroll, who will join us on the night to take you through the story of the PIONEER clinical trial.

Free tickets link in the comments.

Team ILLUMINE, featuring our Hannon Group, will receive up to $25m over five years to take on the challenge of the dark proteome as part of Cancer Grand Challenges.

Full story: www.cruk.cam.ac.uk/news/hannon-...

Our #CamFest event is just one month away, so let's meet the speakers.

Joining us to talk about how our vital research goes from lab to clinic will be Prof Jason Carroll, Dr Rebecca Burrell and Dr Michael Gill.

For free tickets and full details see: www.eventbrite.co.uk/e/the-cancer...

📢 $2M boost for AI in ovarian cancer research

Our Brenton Group joins an international team using AI to improve survival and treatment prediction, with support from Microsoft’s AI for Good Lab.

www.cruk.cam.ac.uk/news/1m-to-a...

Join a panel of our researchers on Thursday 26 March and hear about the journey of two recent discoveries from the lab to the clinic. This talk is a part of this year's #CambridgeFestival and is free to attend.

Find out more and register: www.eventbrite.co.uk/e/the-cancer...

Our Deputy Director Jason Carroll spoke to ITV News Anglia today on #WorldCancerDay. Watch his interview about some of the vital research being undertaken across the Cambridge Institute on local news tonight from 6pm during the segment on the UK government's National Cancer Plan.

Damaged cells may help lung and ovarian cancers resist chemotherapy, but targeting them could improve cancer treatments.

Researchers from the Munoz Espin Lab at the Early Cancer Institute and our Brenton & Narita Groups report the findings in @nataging.nature.com

www.cruk.cam.ac.uk/news/targeti...

A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in
@natgenet.nature.com.

Listen to first author Elizabeth Cooper discuss their findings.
www.cruk.cam.ac.uk/news/new-imm...

We are delighted to share that Senior Group Leader Prof Sir Steve Jackson has been elected as a Fellow of the AACR Academy in the Class of 2026. #AACRFellows recognises extraordinary scientists whose groundbreaking contributions have driven significant innovation and progress in cancer research.

Our Behind the Lab Coat series is back! Get to know the people who are making amazing science happen throughout our Institute.

As a Principal Scientific Associate in one of our in-house Core Facilities, Ian Hall supports scientists across diverse research topics.

A description of the careers lab event with a stock image from a similar event

Are you in Year 12 and looking to explore careers in the sciences? We are excited to announce that applications for our Careers Lab Work Experience Programme for 2026 are now open!

Find out more and apply 👉 www.cruk.cam.ac.uk/students/car...

Hot flush treatment has anti-breast cancer activity, study finds A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.

Find out more 👉 www.cruk.cam.ac.uk/news/hot-flu...

A new trial has found that a progesterone-based drug can support breast cancer treatment when used alongside standard therapy. This began with research at our Institute by Prof Jason Carroll and colleagues, and was taken into the clinic through the #PIONEER trial with Cambridge University Hospitals.

As 2025 comes to a close, we asked our teams for some of their key milestones and moments. From Core Facilities and Operations to our Research Groups and students, everyone has played their part. Here's a quick tour of our achievements as we see the year out.

Our Independent Clinical Fellow Dr Richard Mair is to co-lead the newly established Brain Tumour Research Consortium, funded by a £13.7 million investment from the National Institute for Health and Care Research (NIHR).

Read the announcement: www.cruk.cam.ac.uk/news/dr-rich...

Order of cancer-driving mutations affects the chance of tumour development  - Cancer Research UK Cambridge Institute

New research from our Winton Group reveals that the order of cancer-driving mutations plays an important role in whether tumours in the intestine can develop.

Find out more: www.cruk.cam.ac.uk/news/order-o...

Find out more about Aleksandra's work and the research of the Narita Group: www.cruk.cam.ac.uk/news/aleksan...

Congratulations to Aleksandra Janowska who has won our Postgraduate Student Thesis Prize for her work unlocking new avenues for studying the role of cell identity in the origin of cancer.

The Prize is awarded yearly to a student undertaking an outstanding project during their PhD study with us.

Pioneering trial offers hope on world pancreatic cancer day - Cancer Research UK Cambridge Institute

You can find out more about this news here: www.cruk.cam.ac.uk/news/pioneer...

A new drug for improving the experience of patients receiving treatment for pancreatic cancer has now entered a clinical trial.

Doctors hope the drug, known as VP-002, will allow for lower doses of chemotherapy, reducing its side effects and improving patient experience.

We’re thrilled to partner with Channel 4 on ‘Cancer Detectives: Finding the Cures’ - a new series which is shining a light on three trailblazing scientists taking on cancer, and explores how their work is changing patients’ lives right now. 👇 1/2

Dr @lucygossage.bsky.social was the first keynote at our 2025 Retreat.

Oncologist, professional Ironman champion, and founder of 5K Your Way, Dr Gossage also did her PhD at @cruk-ci.bsky.social.

Recalling this time, she said "completing a PhD and training for an Ironman are remarkably similar!"

Published today in Nature: Molecular switch found to drive pancreatic cancer progression

The Carroll Group has identified a molecular mechanism that helps explain how pancreatic ductal adenocarcinoma (PDAC) progresses, offering a potential path toward more targeted treatments.

Learn more👇
tinyurl.com/34npznuj

@cam.ac.uk @cancerresearchuk.org @pancreaticcanuk.bsky.social @nature.com

Thinking of applying for our Patient & Public Involvement panel?

In this video, Ann Russell, a patient advocate and member of our Scientific Advisory Board, talks through how she first got involved and what working with researchers is like.

Apply by 2 November: www.cruk.cam.ac.uk/patient-and-...

The Narita Group has been awarded a Cancer Research UK Biology to Prevention award. In this short clip, @isadien.bsky.social, a postdoc and clinical lecturer in the group, talks about the aims of the team's work and how the funding enables the next stage of research in the lab and with patients.